Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
RALEIGH, N.C., April 17, 2017 -- PRA Health Sciences, Inc. (NASDAQ:PRAH) will release its first quarter 2017 results after the market closes on Tuesday, April 25, 2017. The Company will also host a conference call on Wednesday, April 26, 2017 at 9:00 a.m. (ET) to discuss the results and guidance with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 10245299. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 10245299.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, an audio playback of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
PRA is one of the world's leading global contract research organizations, by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East, and over 13,000 employees worldwide. Since 2000, PRA has participated in approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: [email protected]
